A jury says Boston Scientific Corp. must pay $431 million in damages in a patent dispute over the medical device maker’s drug-coated stents.
The company said that federal jury in Marshall, Texas reached the damages award in a patent infringement lawsuit brought by Dr. Bruce Saffran. The jury found that Boston Scientific’s Taxus Express and Taxus Liberte stents infringe on a patent that Saffran holds.
Boston Scientific argues the verdict is unsupported by evidence and the law. The Natick, Massachusetts-based company plans to try to overturn the verdict in post-trial motions. If that’s unsuccessful, Boston Scientific says it will appeal.
Stents are tiny, mesh-wire tubes that prop open arteries after they have been surgically cleared of fatty plaque.
Topics Massachusetts
Was this article valuable?
Here are more articles you may enjoy.
First Brands Hit by $286 Million Claim for Alleged Tariffs Fraud 
After Complaint, GEICO Agrees to Modify Cancellation Process That Uses AI 
Acrisure to Cut 2,250 Employees, Citing Advances in Technology and AI 
WTW Sues Former Yacht Team, Howden US Over Defection 
